Ares Trading S.A. - Jun 3, 2021 Form 4 Insider Report for PRECIGEN, INC. (PGEN)

Role
10%+ Owner
Signature
/s/ Cedric Hyde, Authorized Signatory of Merck Serono SA
Stock symbol
PGEN
Transactions as of
Jun 3, 2021
Transactions value $
-$1,064,209
Form type
4
Date filed
6/7/2021, 06:06 PM
Previous filing
Jun 3, 2021
Next filing
Jun 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PGEN Common Stock Sale -$554K -84K -0.34% $6.59 24.6M Jun 3, 2021 Direct F1
transaction PGEN Common Stock Sale -$510K -76.7K -0.31% $6.66 24.5M Jun 4, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Ares Trading, S.A. on April 29, 2021.

Remarks:

This Form 4 is being filed by each of the following persons (together, the Reporting Persons): Ares Trading SA, the direct beneficial owner of the shares, Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, an indirect beneficial owner of the shares, and Merck KGaA, Darmstadt, Germany, an indirect beneficial owner of the shares. Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Merck Serono SA, Aubonne, Switzerland is a wholly owned I indirect subsidiary of Merck KGaA, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 30) and the beneficiary of the two companies.